{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:28:13Z","timestamp":1790263693768,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04145-x","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:54:19Z","timestamp":1753862059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenhui","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"8","key":"4145_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","volume":"16","author":"M Lu","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Anderson H, Boscarino JA, Schmidt MA, Daida YG, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342\u2013e13501341.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"4145_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17474124.2022.2153672","volume":"16","author":"LX Huang","year":"2022","unstructured":"Huang LX, Wang ZL, Jin R, Chen HS, Feng B. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms. Expert Rev Gastroenterol Hepatol. 2022;16(11\u201312):1065\u201378.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"4145_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3350\/cmh.2017.0066","volume":"24","author":"SH Jeong","year":"2018","unstructured":"Jeong SH. Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clin Mol Hepatol. 2018;24(1):10\u20139.","journal-title":"Clin Mol Hepatol"},{"issue":"31","key":"4145_CR4","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.3748\/wjg.v28.i31.4417","volume":"28","author":"ZX Shen","year":"2022","unstructured":"Shen ZX, Wu DD, Xia J, Wang XB, Zheng X, Huang Y, Li BL, Meng ZJ, Gao YH, Qian ZP, et al. Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China. World J Gastroenterol. 2022;28(31):4417\u201330.","journal-title":"World J Gastroenterol"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bpg.2018.06.007","volume":"34\u201335","author":"A Khanna","year":"2018","unstructured":"Khanna A, Leighton J, Lee Wong L, Jones DE. Symptoms of PBC - Pathophysiology and management. Best Pract Res Clin Gastroenterol. 2018;34\u201335:41\u20137.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"4145_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"3","key":"4145_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","volume":"22","author":"SC Huang","year":"2024","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, Liao SH, Hong CM, Lan TY, Yang HC, et al. Metabolic Dysfunction-Associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2024;22(3):581\u2013e590586.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4145_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101155","volume":"29","author":"R Yao","year":"2024","unstructured":"Yao R, Lu S, Xue R, Wang J, Qiu Y, Chen Y, Liu J, Zhu L, Zhan J, Jiang S, et al. NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study. Ann Hepatol. 2024;29(1): 101155.","journal-title":"Ann Hepatol"},{"issue":"2","key":"4145_CR9","doi-asserted-by":"publisher","first-page":"101589","DOI":"10.1016\/j.aohep.2024.101589","volume":"30","author":"S Hong","year":"2024","unstructured":"Hong S, Hao Y, Sun L, Li P, Yang J, Zhang F, He L, Zhang J, Wei H. Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2024;30(2):101589.","journal-title":"Ann Hepatol"},{"issue":"3","key":"4145_CR10","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/MCG.0b013e318261e659","volume":"47","author":"M H\u00edndi","year":"2013","unstructured":"H\u00edndi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013;47(3):e28\u201332.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"4145_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12876-021-01974-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, Shen J, Shang N, Han J, Wang H, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol. 2021;21(1):395.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"4145_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/liv.13644","volume":"38","author":"GY Minuk","year":"2018","unstructured":"Minuk GY, Iliant V, Zhou N, Kaita KD, Wong SG, Peretz D, Uhanova J. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int. 2018;38(6):1110\u20136.","journal-title":"Liver Int"},{"issue":"8","key":"4145_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/apt.12658","volume":"39","author":"GL Wong","year":"2014","unstructured":"Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, Chan HY, Tse CH, Wong VW. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B\u2013a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39(8):883\u201393.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4145_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69(1):394\u2013419.","journal-title":"Hepatology"},{"issue":"5","key":"4145_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"3","key":"4145_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chr\u00e9tien Y, Andr\u00e9ani T, Johanet C, Chazouill\u00e8res O, Poupon R. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137.","journal-title":"Hepatology"},{"issue":"6","key":"4145_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"4145_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"6","key":"4145_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Torriani MSS, Dieterich FJ, Thomas DT. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"3","key":"4145_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"Liver EAftSot","year":"2021","unstructured":"Liver EAftSot. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u2013 2021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"7","key":"4145_CR21","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804\u2013e18121804.","journal-title":"Gastroenterology"},{"key":"4145_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123046","author":"VI Reshetnyak","year":"2022","unstructured":"Reshetnyak VI, Maev IV. Features of lipid metabolism disorders in primary biliary cholangitis. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123046.","journal-title":"Biomedicines"},{"key":"4145_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2353-0","author":"W Jia","year":"2023","unstructured":"Jia W, Li Y, Cheung KCP, Zheng X. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. Sci China Life Sci. 2023. https:\/\/doi.org\/10.1007\/s11427-023-2353-0.","journal-title":"Sci China Life Sci"},{"key":"4145_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ebiom.2016.11.021","volume":"14","author":"C Hardie","year":"2016","unstructured":"Hardie C, Green K, Jopson L, Millar B, Innes B, Pagan S, Tiniakos D, Dyson J, Haniffa M, Bigley V, et al. Early molecular stratification of high-risk primary biliary cholangitis. EBioMedicine. 2016;14:65\u201373.","journal-title":"EBioMedicine"},{"issue":"1","key":"4145_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","volume":"18","author":"H Wang","year":"2021","unstructured":"Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol. 2021;18(1):73\u201391.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4145_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis b. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"2","key":"4145_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2249.2009.03898.x","volume":"156","author":"G Rong","year":"2009","unstructured":"Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, Zhu Y, Lu H, Zhang S, Wang P, et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol. 2009;156(2):217\u201325.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"4145_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2024.01.009","volume":"57","author":"TM Savage","year":"2024","unstructured":"Savage TM, Fortson KT, de Los Santos-Alexis K, Oliveras-Alsina A, Rouanne M, Rae SS, Gamarra JR, Shayya H, Kornberg A, Cavero R, et al. Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis. Immunity. 2024;57(2):303\u2013e318306.","journal-title":"Immunity"},{"issue":"5","key":"4145_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","volume":"67","author":"W Jia","year":"2024","unstructured":"Jia W, Li Y, Cheung KCP, Zheng X. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis. Sci China Life Sci. 2024;67(5):865\u201378.","journal-title":"Sci China Life Sci"},{"issue":"4","key":"4145_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/MEG.0000000000001782","volume":"33","author":"D Iluz-Freundlich","year":"2021","unstructured":"Iluz-Freundlich D, Uhanova J, Van Grubert M, Minuk GY. The impact of primary biliary cholangitis on non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021;33(4):565\u201370.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"4145_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/liv.13562","volume":"38","author":"M Mueller","year":"2018","unstructured":"Mueller M, Castro RE, Thorell A, Marschall HU, Auer N, Herac M, Rodrigues CMP, Trauner M. Ursodeoxycholic acid: effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver Int. 2018;38(3):523\u201331.","journal-title":"Liver Int"},{"issue":"5","key":"4145_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","volume":"54","author":"V Ratziu","year":"2011","unstructured":"Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1011\u20139.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04145-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:38:53Z","timestamp":1757317133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04145-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol adhered to the ethical guidelines of the latest version of the Declaration of Helsinki (2024), and was approved by the Medical Ethics Committee of Peking University People\u2019s Hospital (Approval No. 2022PHB231-001). The requirement of informed consent was waived by the Medical Ethics Committee of Peking University People\u2019s Hospital due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"541"}}